May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- Dragonfly granted Gilead exclusive, worldwide rights to develop and commercialize Dragonfly’s 5T4-targeting immunotherapy DF-7001 for the treatment of cancer and inflammation.
- Gilead has an exclusive, worldwide option to develop and commercialize additional NK cell engager programs by using its Tri-specific NK Engager (TriNKET) platform after the completion of certain preclinical activities.
- Dragonfly will receive $300M up front and is eligible to receive undisclosed opt-in payments and development, regulatory, and commercial milestones, plus up to 20% royalties.
Congrats to Dragonfly Therapeutics and Gilead Sciences for landing DealForma’s May 2022 Top Biopharma Deal. Last month’s Deal of the Month was Harbour BioMed and AstraZeneca’s bispecific antibody deal for cancer treatment. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures